Gabriel S, Creagan E, O'Fallon W M, Jaquith J, Bunch T
Mayo Clinic, Department of Rheumatology, Rochester, MN 55905.
J Rheumatol. 1990 Apr;17(4):460-5.
A pilot study evaluated intravenous methotrexate (MTX) (initial dose 40 mg/m2; final dose, 26 mg/m2), weekly for 12 weeks in 10 patients with rheumatoid arthritis who failed oral MTX. Statistically significant differences were noted for all the response variables examined: joint count (p = 0.0017), morning stiffness (p = 0.014), global assessment (patient, p = 0.0032, physician, p = 0.029), Arthritis Impact Measurement Scale (p = 0.0004), erythrocyte sedimentation rate (p = 0.012), grip strength (right p = 0.044, left p = 0.011). All 7 patients who completed the 12-week treatment period fulfilled the predetermined criteria for response. Intravenous MTX at these doses has potential efficacy in this patient group.
一项试点研究评估了静脉注射甲氨蝶呤（MTX）（初始剂量40mg/m²；最终剂量26mg/m²），对10例口服MTX治疗失败的类风湿性关节炎患者每周给药一次，共给药12周。在所检查的所有反应变量方面均观察到具有统计学意义的差异：关节计数（p = 0.0017）、晨僵（p = 0.014）、整体评估（患者，p = 0.0032，医生，p = 0.029）、关节炎影响测量量表（p = 0.0004）、红细胞沉降率（p = 0.012）、握力（右手p = 0.044，左手p = 0.011）。完成12周治疗期的所有7例患者均符合预定的反应标准。这些剂量的静脉注射MTX在该患者组中具有潜在疗效。
